The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor gene are the most commonly observed genetic alterations in human cancer. The majority of these mutations occur in the conserved central portion of the gene, but there has been little information about the function of this region. Using proteolytic digestion of the 393-amino-acid human p53 protein, we have identified a 191-amino-acid protease-resistant fragment (residues 102-292) that corresponds to the central portion of p53, and we show that this core fragment is the sequence-specific DNA-binding domain of the protein. DNA binding is inhibited by metal chelating agents, and we find that the core domain contains zinc. Proteolytic digests also reveal a 53-amino-acid carboxy-terminal domain which we show to be the tetramerization domain of p53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The DNA binding domain (DBD) of p53 contains four of the five most highly conserved regions of vertebrate p53 and is a hotspot for p53 mutations in cancer, underscoring its importance for function [4,18].”
From Characterization of p53 Family Homologs in Evolutionary Remote Branches of Holozoa (2019) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells
Hartwell, L. (1992) · Cell · doi:10.1016/0092-8674(92)90586-2 · Cited by 770
Cited by
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Self-citationDNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
Hydrogen peroxide sensing, signaling and regulation of transcription factors
Marinho, H. S., Real, C., Cyrne, L., Soares, H., & Antunes, F. (2014) · Redox Biology · doi:10.1016/j.redox.2014.02.006 · Cited by 850
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Redox regulation of transcriptional activators
Sun, Y., & Oberley, L. W. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(96)00109-8 · Cited by 692
Twenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 653
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W. H., Tom, E., Mack, D. H., & Levine, A. J. (2000) · Genes & Development · doi:10.1101/gad.14.8.981 · Cited by 634
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
DNA damage from micronutrient deficiencies is likely to be a major cause of cancer
Ames, B. N. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00070-7 · Cited by 565
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
Self-citationInduction of apoptosis in HeLa cells by trans-activation-deficient p53.
Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., & Oren, M. (1995) · Genes & Development · doi:10.1101/gad.9.17.2170 · Cited by 545
Zinc deficiency, DNA damage and cancer risk
Ho, E. (2004) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.07.005 · Cited by 518
“The DNA-binding activity of p53 is largely mediated by a conformation-sensitive structure in the central portion of the protein (residues 102–292) [36].”
Backgroundp53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
Drosophila p53 Binds a Damage Response Element at the reaper Locus
Brodsky, M. H., Nordstrom, W., Tsang, G., Kwan, E., Rubin, G. M., & Abrams, J. M. (2000) · Cell · doi:10.1016/s0092-8674(00)80627-3 · Cited by 473
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J. M., Frebourg, T., Moreau, V, Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 454
Thioredoxin-dependent Redox Regulation of p53-mediated p21 Activation
Ueno, M., Masutani, H., Arai, R. J., Yamauchi, A., Hirota, K., Sakai, T., Inamoto, T., Yamaoka, Y., Yodoi, J., & Nikaido, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35809 · Cited by 428
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Lee, S., Elenbaas, B., Levine, A., & Griffith, J. (1995) · Cell · doi:10.1016/s0092-8674(05)80006-6 · Cited by 405
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
Ho, E., & Ames, B. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222679399 · Cited by 392
Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Lane, D. P., & Hay, R. T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8458-8467.2000 · Cited by 389
A Glimpse of Structural Biology through X-Ray Crystallography
Shi, Y. (2014) · Cell · doi:10.1016/j.cell.2014.10.051 · Cited by 365
Micronutrients prevent cancer and delay aging
Ames, B. N. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00269-0 · Cited by 346
Jayaraman, L., & Prives, C. (1995) · Cell · doi:10.1016/s0092-8674(05)80007-8 · Cited by 345
The p53 tumor suppressor participates in multiple cell cycle checkpoints
Giono, L. E., & Manfredi, J. J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20689 · Cited by 328
Zhang, W., Geiman, D. E., Shields, J. M., Dang, D. T., Mahatan, C. S., Kaestner, K. H., Biggs, J. R., Kraft, A. S., & Yang, V. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000062200 · Cited by 327
Macleod, K. F., Hu, Y., & Jacks, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01006.x · Cited by 321
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
p53, Oxidative Stress, and Aging
Liu, D., & Xu, Y. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3644 · Cited by 316
High-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR
Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., & Gronenborn, A. M. (1994) · Science · doi:10.1126/science.8023159 · Cited by 307
Role of Cysteine Residues in Regulation of p53 Function
Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P., & Mann, K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3892 · Cited by 306
Kaeser, M. D., & Iggo, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012283399 · Cited by 302
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
Lu, H., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5154 · Cited by 301
Shieh, S.-Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1815 · Cited by 300
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer
DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R. C., Zambetti, G., & Kriwacki, R. W. (2002) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 294
Split-Hand/Split-Foot Malformation Is Caused by Mutations in the p63 Gene on 3q27
Ianakiev, P., Kilpatrick, M. W., Toudjarska, I., Basel, D., Beighton, P., & Tsipouras, P. (2000) · The American Journal of Human Genetics · doi:10.1086/302972 · Cited by 292
Venot, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4668 · Cited by 292
Are vitamin and mineral deficiencies a major cancer risk?
Ames, B. N., & Wakimoto, P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc886 · Cited by 290
p53 Contains Large Unstructured Regions in its Native State
Bell, S., Klein, C., Müller, L., Hansen, S., & Buchner, J. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00848-3 · Cited by 275
The role of tetramerization in p53 function
Chène, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204373 · Cited by 271
Solution structure of the tetrameric minimum transforming domain of p53
Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., & Arrowsmith, C. H. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-877 · Cited by 265
The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation
Esser, C., Scheffner, M., & Höhfeld, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501574200 · Cited by 261
How p53 binds DNA as a tetramer
McLure, K. G., & Lee, P. W. K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3342 · Cited by 260
Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma
D'souza, S., Lau, K. C., Coffin, C. S., & Patel, T. R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i38.5759 · Cited by 257
Truant, R., Antunovic, J., Greenblatt, J., Prives, C., & Cromlish, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.3.1851-1859.1995 · Cited by 255
The N-terminal Domain of p53 is Natively Unfolded
Dawson, R., Müller, L., Dehner, A., Klein, C., Kessler, H., & Buchner, J. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.008 · Cited by 229
Hot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221
Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look
Soussi, T., & May, P. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0425 · Cited by 208
Léveillard, T., Andera, L., Bissonnette, N., Schaeffer, L., Bracco, L., Egly, J. M., & Wasylyk, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00506.x · Cited by 173
Evolutionary history of human colitis-associated colorectal cancer
Baker, A.-M., Cross, W., Curtius, K., Al Bakir, I., Choi, C.-H. R., Davis, H. L., Temko, D., Biswas, S., Martinez, P., Williams, M. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316191 · Cited by 161
(2002) · PubMed · Cited by 143
Thornborrow, E. C., Patel, S., Mastropietro, A. E., Schwartzfarb, E. M., & Manfredi, J. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205069 · Cited by 132
“At its amino-terminus, the p53 protein contains a potent transcriptional activation domain (Fields and Jang, 1990) which is linked to a central core domain that mediates sequence-speci®c DNA binding (Bargonetti et al., 1993; Pavletich et al., 1993;Wang et al., 1993).”
BackgroundWild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
“The DNA-binding domain of wild-type p53 resides between amino acids 100 and 300 (3, 58, 81), whereas transactivation function requires amino acids 1 to 42 (21, 57, 61, 76) of the protein.”
BackgroundStructure of the p53 Core Domain Dimer Bound to DNA
Ho, W. C., Fitzgerald, M. X., & Marmorstein, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603634200 · Cited by 118
Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
Jordan, J. J., Menendez, D., Inga, A., Nourredine, M., Bell, D., & Resnick, M. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000104 · Cited by 103
“The DNA binding domain of p53 has been shown in vitro to bind DNA in the absence of the oligomerization domain and that dimeric p53 can bind to half-sites in a cooperative fashion independent of tetramerization [22,105].”
BackgroundTF-DUBTACs Stabilize Tumor Suppressor Transcription Factors
Liu, J., Yu, X., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04824 · Cited by 73
Lactylation modification of HIF-1α enhances its stability by blocking VHL recognition
Li, C., Fu, C., Zhou, W., Li, H., Liu, Z., Wu, G., He, T., Shen, M., & Liu, H. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02366-x · Cited by 60
“…in other transcription fac-tors—p53 Ser15 phosphorylation and Lys382 acetylation enhance DNA binding despite their distance from the core domain [29–31], FOXO3a Ser253 phosphorylation regulates 14-3-3 binding and localization [32], and STAT3 Lys685 acetylation stabilizes dimerization outside its…”
Characterization of p53 Family Homologs in Evolutionary Remote Branches of Holozoa
Bartas, M., Brázda, V., Červeň, J., & Pečinka, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010006 · Cited by 29
R248Q mutation—Beyond p53‐DNA binding
Ng, J. W. K., Lama, D., Lukman, S., Lane, D. P., Verma, C. S., & Sim, A. Y. L. (2015) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24940 · Cited by 28
Metadata
- Authors
- Pavletich, N. P., Chambers, K. A., & Pabo, C. O.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1993-12-01
- Volume
- 7
- Issue
- 12b
- Pages
- 2556-2564
- ISSN
- 0890-9369 (ISSN-L)
- OpenAlex
- W2128583894
- Cited by
- 521
- References
- 20
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.